Cargando…

An Update on Current Therapeutic Drugs Treating COVID-19

The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Renyi, Wang, Lujing, Kuo, Hsiao-Chen Dina, Shannar, Ahmad, Peter, Rebecca, Chou, Pochung Jordan, Li, Shanyi, Hudlikar, Rasika, Liu, Xia, Liu, Zhigang, Poiani, George J., Amorosa, Louis, Brunetti, Luigi, Kong, Ah-Ng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211915/
https://www.ncbi.nlm.nih.gov/pubmed/32395418
http://dx.doi.org/10.1007/s40495-020-00216-7
_version_ 1783531538984468480
author Wu, Renyi
Wang, Lujing
Kuo, Hsiao-Chen Dina
Shannar, Ahmad
Peter, Rebecca
Chou, Pochung Jordan
Li, Shanyi
Hudlikar, Rasika
Liu, Xia
Liu, Zhigang
Poiani, George J.
Amorosa, Louis
Brunetti, Luigi
Kong, Ah-Ng
author_facet Wu, Renyi
Wang, Lujing
Kuo, Hsiao-Chen Dina
Shannar, Ahmad
Peter, Rebecca
Chou, Pochung Jordan
Li, Shanyi
Hudlikar, Rasika
Liu, Xia
Liu, Zhigang
Poiani, George J.
Amorosa, Louis
Brunetti, Luigi
Kong, Ah-Ng
author_sort Wu, Renyi
collection PubMed
description The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeutic agents against the virus. Current clinical management includes infection prevention and control measures and supportive care including supplemental oxygen and mechanical ventilatory support. Evolving research and clinical data regarding the virologic SARS-CoV-2 suggest a potential list of repurposed drugs with appropriate pharmacological effects and therapeutic efficacies in treating COVID-19 patients. In this review, we will update and summarize the most common and plausible drugs for the treatment of COVID-19 patients. These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and oseltamivir), and supporting agents (Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others. We hope that this review will provide useful and most updated therapeutic drugs to prevent, control, and treat COVID-19 patients until the approval of vaccines and specific drugs targeting SARS-CoV-2.
format Online
Article
Text
id pubmed-7211915
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-72119152020-05-11 An Update on Current Therapeutic Drugs Treating COVID-19 Wu, Renyi Wang, Lujing Kuo, Hsiao-Chen Dina Shannar, Ahmad Peter, Rebecca Chou, Pochung Jordan Li, Shanyi Hudlikar, Rasika Liu, Xia Liu, Zhigang Poiani, George J. Amorosa, Louis Brunetti, Luigi Kong, Ah-Ng Curr Pharmacol Rep Hot Topic The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeutic agents against the virus. Current clinical management includes infection prevention and control measures and supportive care including supplemental oxygen and mechanical ventilatory support. Evolving research and clinical data regarding the virologic SARS-CoV-2 suggest a potential list of repurposed drugs with appropriate pharmacological effects and therapeutic efficacies in treating COVID-19 patients. In this review, we will update and summarize the most common and plausible drugs for the treatment of COVID-19 patients. These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and oseltamivir), and supporting agents (Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others. We hope that this review will provide useful and most updated therapeutic drugs to prevent, control, and treat COVID-19 patients until the approval of vaccines and specific drugs targeting SARS-CoV-2. Springer International Publishing 2020-05-11 2020 /pmc/articles/PMC7211915/ /pubmed/32395418 http://dx.doi.org/10.1007/s40495-020-00216-7 Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Hot Topic
Wu, Renyi
Wang, Lujing
Kuo, Hsiao-Chen Dina
Shannar, Ahmad
Peter, Rebecca
Chou, Pochung Jordan
Li, Shanyi
Hudlikar, Rasika
Liu, Xia
Liu, Zhigang
Poiani, George J.
Amorosa, Louis
Brunetti, Luigi
Kong, Ah-Ng
An Update on Current Therapeutic Drugs Treating COVID-19
title An Update on Current Therapeutic Drugs Treating COVID-19
title_full An Update on Current Therapeutic Drugs Treating COVID-19
title_fullStr An Update on Current Therapeutic Drugs Treating COVID-19
title_full_unstemmed An Update on Current Therapeutic Drugs Treating COVID-19
title_short An Update on Current Therapeutic Drugs Treating COVID-19
title_sort update on current therapeutic drugs treating covid-19
topic Hot Topic
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211915/
https://www.ncbi.nlm.nih.gov/pubmed/32395418
http://dx.doi.org/10.1007/s40495-020-00216-7
work_keys_str_mv AT wurenyi anupdateoncurrenttherapeuticdrugstreatingcovid19
AT wanglujing anupdateoncurrenttherapeuticdrugstreatingcovid19
AT kuohsiaochendina anupdateoncurrenttherapeuticdrugstreatingcovid19
AT shannarahmad anupdateoncurrenttherapeuticdrugstreatingcovid19
AT peterrebecca anupdateoncurrenttherapeuticdrugstreatingcovid19
AT choupochungjordan anupdateoncurrenttherapeuticdrugstreatingcovid19
AT lishanyi anupdateoncurrenttherapeuticdrugstreatingcovid19
AT hudlikarrasika anupdateoncurrenttherapeuticdrugstreatingcovid19
AT liuxia anupdateoncurrenttherapeuticdrugstreatingcovid19
AT liuzhigang anupdateoncurrenttherapeuticdrugstreatingcovid19
AT poianigeorgej anupdateoncurrenttherapeuticdrugstreatingcovid19
AT amorosalouis anupdateoncurrenttherapeuticdrugstreatingcovid19
AT brunettiluigi anupdateoncurrenttherapeuticdrugstreatingcovid19
AT kongahng anupdateoncurrenttherapeuticdrugstreatingcovid19
AT wurenyi updateoncurrenttherapeuticdrugstreatingcovid19
AT wanglujing updateoncurrenttherapeuticdrugstreatingcovid19
AT kuohsiaochendina updateoncurrenttherapeuticdrugstreatingcovid19
AT shannarahmad updateoncurrenttherapeuticdrugstreatingcovid19
AT peterrebecca updateoncurrenttherapeuticdrugstreatingcovid19
AT choupochungjordan updateoncurrenttherapeuticdrugstreatingcovid19
AT lishanyi updateoncurrenttherapeuticdrugstreatingcovid19
AT hudlikarrasika updateoncurrenttherapeuticdrugstreatingcovid19
AT liuxia updateoncurrenttherapeuticdrugstreatingcovid19
AT liuzhigang updateoncurrenttherapeuticdrugstreatingcovid19
AT poianigeorgej updateoncurrenttherapeuticdrugstreatingcovid19
AT amorosalouis updateoncurrenttherapeuticdrugstreatingcovid19
AT brunettiluigi updateoncurrenttherapeuticdrugstreatingcovid19
AT kongahng updateoncurrenttherapeuticdrugstreatingcovid19